tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Márquez JA and Serrano R Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. 1996 FEBS Lett. pmid:8612770
Stoller G et al. An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. 1996 FEBS Lett. pmid:8612805
Pham SM et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. 1996 J. Thorac. Cardiovasc. Surg. pmid:8614136
Igarashi O et al. B7-1 synergizes with interleukin-12 in interleukin-2 receptor alpha expression by mouse T helper 1 clones. 1996 Eur. J. Immunol. pmid:8617295
Rappersberger K et al. Clearing of psoriasis by a novel immunosuppressive macrolide. 1996 J. Invest. Dermatol. pmid:8618008
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Takeda M et al. Methotrexate in rescue therapy for xenotransplanted lungs in primates. 1996 Transplant. Proc. pmid:8623402
Andereggen E et al. Immunohistological study of islet xenograft rejection in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623420
Horimoto H et al. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506. 1996 Transplant. Proc. pmid:8623421
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
DiGiuseppe JA et al. Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. 1996 Arch. Pathol. Lab. Med. pmid:8629906
Kinoshita I et al. Myoblast transplantation in monkeys: control of immune response by FK506. 1996 J. Neuropathol. Exp. Neurol. pmid:8642394
Singh N et al. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. 1996 Surgery pmid:8644012
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Tanida I et al. Yeast Cls2p/Csg2p localized on the endoplasmic reticulum membrane regulates a non-exchangeable intracellular Ca2+ pool cooperatively with calcineurin. 1996 FEBS Lett. pmid:8566225
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Yamada T et al. Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8907927
Rossi G et al. Results of orthotopic liver-small bowel transplantation in the pig using different immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907932
Platz KP et al. Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation. 1996 Transplant. Proc. pmid:8907933
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Hayashi K et al. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats. 1996 Jpn. J. Pharmacol. pmid:8822088
Sasahara Y et al. Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification. 1996 J. Biol. Chem. pmid:8824230
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Matsuda H et al. Interactions of FK506 (tacrolimus) with clinically important drugs. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:8824931
Moriwaki A et al. Immunosuppressant FK506 prevents mossy fiber sprouting induced by kindling stimulation. 1996 Neurosci. Res. pmid:8829156
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Hashino S et al. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation. 1996 Leuk. Lymphoma pmid:8726416
Steiner JP et al. Immunophilin regulation of neurotransmitter release. 1996 Mol. Med. pmid:8784785
Herzog D et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8732907
Licitra EJ and Liu JO A three-hybrid system for detecting small ligand-protein receptor interactions. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8917502
Woodle ES et al. Treatment of acute glomerular rejection with FK 506. 1996 Clin Transplant pmid:8826664
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Golling M et al. Tacrolimus reduction improves glucose metabolism and insulin secretion after liver transplantation. 1996 Transplant. Proc. pmid:8962234
Platz KP et al. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients. 1996 Transplant. Proc. pmid:8962235
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Johnson MW et al. Hepatitis C viral infection in liver transplantation. 1996 Arch Surg pmid:8611094
Lamb GD and Stephenson DG Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. 1996 J. Physiol. (Lond.) pmid:8842013
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Tanaka K et al. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. 1996 Pharm. Res. pmid:8842048
Bader A et al. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8935714
Borvak J et al. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. 1996 J. Infect. Dis. pmid:8843228
Galat A A large-scale processing of kinetic data files with derivation of the inhibitory constant Ki: an application to proline isomerases. 1996 Comput. Chem. pmid:8936426
Borg AJ et al. 15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes. 1996 Transpl. Immunol. pmid:8843590
Chen BG et al. Inhibition by CsA and FK506 of the in vitro proliferative response of gamma delta T cells on stimulation with anti-TCR delta monoclonal antibody. 1996 Transpl. Immunol. pmid:8843593
Andrews PA et al. Racial variation in dosage requirements of tacrolimus. 1996 Lancet pmid:8937292
Toyota N et al. Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells. 1996 Arch. Dermatol. Res. pmid:8844128
Owens-Grillo JK et al. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. 1996 J. Biol. Chem. pmid:8662874
Kralli A and Yamamoto KR An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. 1996 J. Biol. Chem. pmid:8663352
Okada K et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. 1996 Ophthalmologica pmid:8738464
Wagner K et al. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. 1996 Clin. Nephrol. pmid:8738666
Hohage H et al. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. 1996 Clin. Nephrol. pmid:8738668
Herget S et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. 1996 Clin. Nephrol. pmid:8738671
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Ezeamuzie CI Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. 1996 Int. J. Immunopharmacol. pmid:8894806
Ockenfels HM et al. The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes. 1996 Skin Pharmacol. pmid:8896120
Nash RA et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 1996 Blood pmid:8896434
Rozen TD et al. Treatment-refractory cyclosporine-associated headache: relief with conversion to FK-506. 1996 Neurology pmid:8909459
Dawson S et al. UCLA liver transplantation: analysis of immunological factors affecting outcome. 1996 Artif Organs pmid:8896726
Bell A et al. The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. 1996 Gen. Pharmacol. pmid:8909976
Kashu Y et al. Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. 1996 Artif Organs pmid:8896731
Weigao C [Limb allograft in rats: studies on optimal maintenance dose of FK506 and development of graft-versus-host-disease (GVHD)]. 1996 Fukuoka Igaku Zasshi pmid:8913057
Okadome T et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. 1996 J. Biol. Chem. pmid:8702959
Rahfeld JU et al. Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli. Similarity to Mip-like proteins of pathogenic bacteria. 1996 J. Biol. Chem. pmid:8703024
Pullicino P et al. Posterior leucoencephalopathy syndrome. 1996 Lancet pmid:8684128
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Huntress JD and Papadakos PJ The role of calcium-channel antagonists in solid organ transplantation. 1996 New Horiz pmid:8689268
[Transplantation medicine. Tacrolimus increases survival chances after organ transplantation. XVI International Congress of the Transplantation Society. 25-30 August 1996 Barcelona]. 1996 Dtsch. Med. Wochenschr. pmid:9447224
Morris RE Transplantation. Beware: shifting paradigms ahead. 1996 Dec 21-28 Lancet pmid:8973504
Shultz SL and Meriney DK Cyclosporine and tacrolimus: a comparison of immunosuppressants used for liver transplantation. 1996 Jul-Aug Dimens Crit Care Nurs pmid:8717641
Frezza EE et al. Small bowel transplantation: current progress and clinical application. 1996 Mar-Apr Hepatogastroenterology pmid:8714229
Seifeldin R et al. Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus. 1996 May-Jun Clin Ther pmid:8829025
Cumming DV et al. Pharmacological preconditioning of primary rat cardiac myocytes by FK506. 1996 Sep-Oct Basic Res. Cardiol. pmid:8922254
Soin AS and Jamieson NV Lessons learnt from the multicentre randomized trials of tacrolimus in liver transplantation. 1996 Sep-Oct Natl Med J India pmid:8937063
Kokudo N et al. Allogeneic hepatocyte and fetal liver transplantation and xenogeneic hepatocyte transplantation for Nagase's analbuminemic rats. 1996 Sep-Oct Cell Transplant pmid:8889223
Furukawa M et al. Analysis of PCR microchimerism induced by intrathymic inoculation of donor alloantigens in rats. 1996 Sep-Oct Cell Transplant pmid:8889237
Singh N et al. Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447904
Jindal RM Post-transplant hyperlipidaemia. 1997 Postgrad Med J pmid:9497947
Guerini D Calcineurin: not just a simple protein phosphatase. 1997 Biochem. Biophys. Res. Commun. pmid:9199180
Krüger M et al. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells. 1997 Naunyn Schmiedebergs Arch. Pharmacol. pmid:9349628
Zhang Q et al. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. 1997 Ther Drug Monit pmid:9263391
Hikita N et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. 1997 Invest. Ophthalmol. Vis. Sci. pmid:9112986
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Lang T et al. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. 1997 Transplantation pmid:9415561
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
ten Berge RJ and Schellekens PT [Immunology in clinical practice. VI. Current immunosuppressive drugs]. 1997 Ned Tijdschr Geneeskd pmid:9550813